Brokerages Set Vera Therapeutics, Inc. (NASDAQ:VERA) Price Target at $84.58

by · The Cerbat Gem

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) have earned a consensus rating of “Moderate Buy” from the thirteen analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eleven have given a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $84.5833.

VERA has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Friday, July 17th. William Blair reiterated an “outperform” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Evercore set a $91.00 price target on shares of Vera Therapeutics in a report on Friday, May 15th. Needham & Company LLC set a $125.00 price target on shares of Vera Therapeutics in a report on Wednesday, July 8th. Finally, The Goldman Sachs Group restated a “buy” rating and issued a $90.00 price objective on shares of Vera Therapeutics in a research report on Tuesday, June 2nd.

Check Out Our Latest Report on Vera Therapeutics

Vera Therapeutics Price Performance

Vera Therapeutics stock opened at $35.18 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.64 and a quick ratio of 13.64. The business has a 50 day simple moving average of $37.02 and a 200-day simple moving average of $40.01. Vera Therapeutics has a 12 month low of $19.07 and a 12 month high of $56.05. The stock has a market capitalization of $2.53 billion, a PE ratio of -6.35 and a beta of 0.92.

Vera Therapeutics (NASDAQ:VERA – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same quarter in the previous year, the firm posted ($0.81) EPS. Equities analysts predict that Vera Therapeutics will post -6.37 earnings per share for the current year.

Insider Activity

In other news, CEO Marshall Fordyce sold 46,250 shares of the stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the completion of the transaction, the chief executive officer directly owned 151,994 shares of the company’s stock, valued at approximately $6,429,346.20. This represents a 23.33% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 83,250 shares of company stock worth $3,337,770. Corporate insiders own 15.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. UBS Group AG boosted its position in shares of Vera Therapeutics by 27.9% during the 4th quarter. UBS Group AG now owns 207,289 shares of the company’s stock worth $10,497,000 after purchasing an additional 45,214 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Vera Therapeutics by 11.9% during the 4th quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock worth $180,805,000 after purchasing an additional 379,748 shares during the period. Swedbank AB increased its holdings in shares of Vera Therapeutics by 142.4% in the 4th quarter. Swedbank AB now owns 121,200 shares of the company’s stock valued at $6,138,000 after purchasing an additional 71,200 shares in the last quarter. AMI Asset Management Corp purchased a new position in shares of Vera Therapeutics in the 4th quarter valued at about $1,444,000. Finally, TimesSquare Capital Management LLC purchased a new position in shares of Vera Therapeutics in the 4th quarter valued at about $12,785,000. Institutional investors and hedge funds own 99.21% of the company’s stock.

About Vera Therapeutics

(Get Free Report)

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.

Featured Stories